FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.
You may also be interested in...
FDA Compounding Policy To Have Day In Court In December
Ten pharmacies challenging the agency's compounding policy say the lawsuit is an effort to stop "FDA's end-run on the Western States decision," which threw out restrictions on advertising for compounding products.
FDA Compounding Policy To Have Day In Court In December
Ten pharmacies challenging the agency's compounding policy say the lawsuit is an effort to stop "FDA's end-run on the Western States decision," which threw out restrictions on advertising for compounding products.
Pharmacy's Compounding Resembles Rx Manufacturing Operation, FDA Says
FDA "warning letter" states that Lincare and Reliant Pharmacy produce "essentially copies of commercially available drugs" without documented patient-specific medical need. This practice goes beyond the scope of traditional compounding, the letter states.